{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination&page=12", "query": { "intervention": "Combination", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 19419, "total_pages": 1942, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T17:35:31.560Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00158236", "title": "Abuse Potential of Buprenorphine and Naloxone in Non-Dependent Opioid Users", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Opioid-Related Disorders" ], "interventions": [ { "name": "Buprenorphine", "type": "DRUG" }, { "name": "Buprenorphine and Naloxone", "type": "DRUG" }, { "name": "Hydromorphone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute on Drug Abuse (NIDA)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 7, "start_date": "1997-01", "completion_date": "1998-03", "has_results": false, "last_update_posted_date": "2017-01-12", "last_synced_at": "2026-10-23T17:35:31.560Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00158236" }, { "nct_id": "NCT06741644", "title": "A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "CS2009", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CStone Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 800, "start_date": "2025-02-24", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-23T17:35:31.560Z", "location_count": 2, "location_summary": "Los Angeles, California • Irving, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Irving", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06741644" }, { "nct_id": "NCT00286234", "title": "Niacin, N-3 Fatty Acids and Insulin Resistance", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Metabolic Syndrome", "Hypertriglyceridemia" ], "interventions": [ { "name": "omega-3 acid ethyl esters", "type": "DRUG" }, { "name": "extended release niacin", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "combined treatment", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of South Dakota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "40 Years to 69 Years" }, "enrollment_count": 68, "start_date": "2007-10", "completion_date": "2008-12", "has_results": true, "last_update_posted_date": "2021-10-26", "last_synced_at": "2026-10-23T17:35:31.560Z", "location_count": 1, "location_summary": "Sioux Falls, South Dakota", "locations": [ { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00286234" }, { "nct_id": "NCT07710534", "title": "Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed / Refractory AML", "High Risk Myelodysplastic Syndrome", "High Risk Myeloproliferative Neoplasms" ], "interventions": [ { "name": "Decitabine-cedazuridine plus venetoclax (DEC-C+VEN)", "type": "DRUG" }, { "name": "Azacitidine plus venetoclax (AZA+VEN)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2026-09-16", "completion_date": "2033-12-31", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-23T17:35:31.560Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07710534" }, { "nct_id": "NCT06943664", "title": "Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Non-Small Cell Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Refractory Lung Non-Small Cell Carcinoma", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" }, { "name": "Cetuximab Sarotalocan Sodium", "type": "BIOLOGICAL" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Electronic Health Record Review", "type": "OTHER" }, { "name": "Endobronchial Ultrasound Bronchoscopy", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Photoimmunotherapy", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Robotic Bronchoscopy", "type": "PROCEDURE" }, { "name": "Video-Assisted Thoracic Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2026-08-15", "completion_date": "2028-05-01", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-23T17:35:31.560Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06943664" }, { "nct_id": "NCT00295932", "title": "Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 79, "start_date": "2005-12-13", "completion_date": "2018-03-11", "has_results": true, "last_update_posted_date": "2018-11-20", "last_synced_at": "2026-10-23T17:35:31.560Z", "location_count": 8, "location_summary": "Atlanta, Georgia • Basking Ridge, New Jersey • New Brunswick, New Jersey + 4 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00295932" }, { "nct_id": "NCT00251498", "title": "Phase II Study of Cetuximab in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Veeda Oncology", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 82, "start_date": null, "completion_date": "2007-10", "has_results": false, "last_update_posted_date": "2008-08-21", "last_synced_at": "2026-10-23T17:35:31.560Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00251498" }, { "nct_id": "NCT05264129", "title": "Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Episodic Migraine" ], "interventions": [ { "name": "Atogepant", "type": "DRUG" }, { "name": "Ubrogepant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 263, "start_date": "2022-03-07", "completion_date": "2023-04-04", "has_results": true, "last_update_posted_date": "2024-10-08", "last_synced_at": "2026-10-23T17:35:31.560Z", "location_count": 37, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Oceanside, California + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Oceanside", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05264129" }, { "nct_id": "NCT06654037", "title": "Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Microsatellite Stable Colorectal Carcinoma", "Refractory Microsatellite Stable Colorectal Carcinoma", "Stage IV Colorectal Cancer AJCC v8" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Radiologic Imaging Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2025-04-18", "completion_date": "2027-04-01", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-23T17:35:31.560Z", "location_count": 8, "location_summary": "Irvine, California • Orange, California • The Bronx, New York + 3 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "The Bronx", "state": "New York" }, { "city": "The Bronx", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06654037" }, { "nct_id": "NCT07597902", "title": "SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Post-acute Sequelae of COVID-19", "Long COVID" ], "interventions": [ { "name": "Valacyclovir", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" }, { "name": "Paxlovid", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 150, "start_date": "2026-06-01", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-10-23T17:35:31.560Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07597902" } ] }